Illustration: Gabriella Turrisi/Axios
Generate Biomedicines, a Flagship Pioneering-backed AI biotech that's raised nearly $700 million, filed for an IPO on Wednesday evening.
The latest: Generate dosed its first patient in a Phase 3 trial of its severe asthma drug candidate late last month.
